| Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
| Journal website https://www.thejh.org |
Case Report
Volume 12, Number 3, June 2023, pages 138-144
Donor Cell Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
Table
| Case | Recipient diagnosis | Donor age | Donor gender | Donor ABO compatibility | Donor HLA matching | Donor CMV status | Donor CHIP status | Genes | Conditioning regimen | Time to DCL development | DCL type | DCL characteristics | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DCL, an abbreviation for donor cell leukemia, represents the occurrence of leukemia originating from the transplanted donor cells. The table includes information on ABO blood type compatibility, HLA matching, CMV status, and CHIP status. Additionally, DCL type is classified as either mixed chimerism, indicating the coexistence of recipient and donor cells, or pure donor chimerism, denoting complete replacement of recipient cells by donor cells. HLA: human leukocyte antigen; CMV: cytomegalovirus; CHIP: clonal hematopoiesis of indeterminate potential; DCL: donor cell leukemia. | |||||||||||||
| 1 | Acute myeloid leukemia | 52 | Male | Compatible | Fully matched | Positive | Positive | DNMT3A, TET2, ASXL1, TP53, SF3B1, SRSF2, IDH1, IDH2 | Myeloablative | 12 months | Mixed chimerism | Expansion of donor-derived leukemic clone | Relapse |
| 2 | Myelodysplastic syndrome | 65 | Female | Compatible | Partially matched | Negative | Negative | SF3B1, U2AF1, TP53, RUNX1, ASXL1, DNMT3A, TET2, EZH2 | Reduced intensity | 24 months | Pure donor chimerism | Complete replacement of recipient cells by donor cells | Remission |
| 3 | Chronic lymphocytic leukemia | 72 | Male | Compatible | Fully matched | Positive | Not available | TP53, NOTCH1, SF3B1, ATM, BIRC3, POT1, XPO1 | Myeloablative | 6 months | Mixed chimerism | Coexistence of recipient and donor cells | Death |
| 4 | Non-Hodgkin lymphoma | 46 | Female | Incompatible | Partially matched | Not available | Positive | TP53, MYD88, CD79B, EZH2, PIM1, CARD11 | Reduced intensity | 18 months | Pure donor chimerism | Complete replacement of recipient cells by donor cells | Remission |